Recent studies have shown that giving vaginal progesterone to women carrying twins with a short cervix can lower the chances of early preterm birth and reduce health problems in newborns. However, it is still unclear whether using progesterone during pregnancy has any long-term effects on the mental health and cognitive development of the twins as they grow older.
To bridge this knowledge gap, Alfredo PERALES, Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain, and colleagues aimed to assess the mental health and thinking abilities of children aged 6 to 9 years, whose mothers had taken part in a study comparing two daily doses of vaginal progesterone (200 mg and 400 mg) with a placebo during twin pregnancies to prevent preterm birth.
For this purpose, the researchers conducted a follow-up of a multicenter, double-blind randomized trial with three groups—placebo, 200 mg/day, and 400 mg/day vaginal progesterone—given from 20 to 34 weeks of pregnancy or until delivery. At 6 to 9 years of age, children were assessed using the Child Behavior Checklist for behavioral and emotional issues, and Raven’s Colored Progressive Matrices for non-verbal intelligence. All participants and assessors were blinded to treatment allocation. Analyses were done intention-to-treat, with P < 0.05 considered statistically significant.
Key findings were as follows:
- The study included 206 children born to 104 mothers, accounting for 35.4% of the original trial participants.
- Of these, 75 children were exposed to 200 mg/day of vaginal progesterone, 63 to 400 mg/day, and 68 to placebo.
- There were no notable differences in maternal background, pregnancy, or neonatal characteristics between participants and non-participants, or among the three groups.
- Children exposed to progesterone (either dose) showed no significant differences in behavioral or emotional outcomes compared to those in the placebo group, based on the Child Behavior Checklist scores.
- The average total scores on the Child Behavior Checklist were similar across groups: 31.08 in the 200 mg group, 37.48 in the 400 mg group, 34.00 in the combined group, and 34.60 in the placebo group.
- The Raven’s test results, which measured non-verbal intelligence, showed slightly higher average percentiles in the progesterone groups (63.11 and 60.40) compared to the placebo group (59.40), but these differences were not statistically significant.
Overall, the study concluded that prenatal administration of vaginal progesterone—at either dosage—during the second half of pregnancy did not adversely influence the cognitive or psychological development of children born from dichorionic twin pregnancies.
"These findings provide reassuring evidence that the use of vaginal progesterone for preventing preterm birth in twin gestations does not carry long-term developmental risks for children, supporting its continued use in appropriate clinical scenarios," the researchers wrote.
Reference:
PERALES, A., AVIÑO, J., DIAZ-MARTINEZ, A., CONDE-AGUDELO, A., ROMERO, R., ROJO, L., & SERRA, V. (2025). Prenatal exposure to vaginal progesterone for the prevention of preterm birth is not associated with abnormal psychopathological and cognitive profiles in dichorionic twins at 6 to 9 years of age: A follow-up study of a randomized controlled trial. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2025.04.056
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.